Abstract
Traditionally, amyotrophic lateral sclerosis (ALS) has been considered to be a disorder in which the primary pathology resides in the degeneration of motor neurons, giving rise to progressive, diffuse muscle wasting, weakness, and spasticity. Evidence of cognitive impairment in ALS is overwhelming.
Although we found few relations between particular scales of Cognistat and the other measurements, findings suggest that Cognistat (NCSE) may be useful screening scale in identifying major cognitive impairments among the ALS patients.